Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity

BJU International

Volumn 107, Issue 11, 2011, Pages 1786-1792

  Gamé, Xavier ^a   Khan, Shahid ^a   Panicker, Jalesh N ^a   Kalsi, Vinay ^a   Dalton, Catherine ^a   Elneil, Sohier ^a   Hamid, Rizwan ^a   Dasgupta, Prokar ^a,b   Fowler, Clare J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

botulinum toxin; detrusor; idiopathic; neurogenic; overactivity; quality of life

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANXIETY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFECT; EUROQOL 5D; FEMALE; HUMAN; IDIOPATHIC DISEASE; INCONTINENCE IMPACT QUESTIONNAIRE 7; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; URINE INCONTINENCE; UROGENITAL DISTRESS INVENTORY 6; UROGENITAL TRACT DISEASE;

ADULT; BOTULINUM TOXINS, TYPE A; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INJECTIONS, INTRALESIONAL; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 79956367461     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09791.x     Document Type: Article

References (19)

1. Karsenty G, Denys P, Amarenco G, et al,. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53: 275-87 (Pubitemid 350296587)
2. Apostolidis A, Dasgupta P, Denys P, et al,. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol 2009; 55: 100-19
3. Schurch B, de Seze M, Denys P, et al,. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200 (Pubitemid 40825713)
4. Giannantoni A, Mearini E, Del Zingaro M, Porena M,. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009; 55: 705-11
5. Grosse J, Kramer G, Stohrer M,. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-9 (Pubitemid 40521915)
6. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B,. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006; 68: 1193-7 (Pubitemid 44880353)
7. Reitz A, Denys P, Fermanian C, et al,. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007; 52: 1729-35 (Pubitemid 350064538)
8. Sahai A, Dowson C, Khan MS, Dasgupta P,. Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity. Urology 2009; 75: 552-8
9. Kalsi V, Apostolidis A, Popat R, et al,. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49: 528-35 (Pubitemid 43259564)
10. Popat R, Apostolidis A, Kalsi V, et al,. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174: 984-9 (Pubitemid 41140656)
11. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA,. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995; 14: 131-9
12. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208
13. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P,. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92: 325-6 (Pubitemid 36966603)
14. Kessler TM, Kahn S, Panicker J, et al,. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009; 113: 1046-51
15. Sahai A, Dowson C, Khan MS, Dasgupta P,. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009; 103: 1509-15
16. Schurch B, Denys P, Kozma CM, et al,. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007; 52: 850-8
17. Haywood KL, Garratt AM, Lall R, Smith JF, Lamb SE,. EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness. Qual Life Res 2008; 17: 475-83
18. Tincello D, Sculpher M, Tunn R, et al,. Patient characteristics impacting health state index scores, measured by the EQ-5D of females with stress urinary incontinence symptoms. Value Health 2010; 13: 112-8
19. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD,. Urinary incontinence and depression. J Urol 1999; 162: 82-4 (Pubitemid 29420885)